What Is Claimed Is:

## CLAIMS

1. An antibody or antigen-binding portion thereof, wherein said antibody or antigen-binding portion thereof specifically binds to an E-protein, Domain II (E-DII) epitope of a Yellow Fever (YF) Virus, wherein the E-DII epitope comprises the amino acids at positions 93, 104 and 106 of the YF E-DII, which positions correspond to those of the 17D YF vaccine strain.

2. The antibody or antigen-binding portion thereof of claim 1, wherein the antibody or antigen-binding portion thereof comprises three CDRs of a heavy chain variable region (VH), wherein the VH comprises an amino acid sequence selected from the group consisting of SEQ ID. NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, and 36, and wherein the antibody or antigen-binding portion thereof comprises three CDRs of a light chain variable region (VL), wherein the VL comprises an amino acid sequence selected from the group consisting of SEQ ID. NOs: 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, and 73.

3. The antibody or antigen-binding portion thereof claim 1 or 2, wherein the antibody or antigen-binding portion thereof comprises a VH, wherein the VH comprises an amino acid sequence selected from the group consisting of SEQ ID. NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, and 36, and wherein the antibody or antigen-binding portion thereof comprises a VL, wherein the VL comprises an amino acid sequence selected from the group consisting of SEQ ID. NOs: 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, and 73.

4. The antibody or antigen-binding portion thereof of any of the preceding claims, wherein the antibody or antigen-binding portion thereof is a human antibody or antigen-binding portion thereof, a monoclonal antibody or antigen-binding portion thereof, a chimeric antibody or antigen-binding portion thereof, or a humanized antibody or antigen-binding portion thereof.

5. The antibody or antigen-binding portion thereof of any of the preceding claims, wherein the antibody or antigen-binding portion thereof is a single chain antibody or antigen-binding portion thereof, a F(ab') 2 fragment, a dAb fragment, a Fab fragment, or a Fv fragment.

6. The antibody or antigen-binding portion thereof of any of the preceding claims, wherein the antibody or antigen-binding portion thereof is an isolated antibody or antigen-binding portion thereof.

7. A composition comprising an antibody or antigen-binding portion thereof of any of the preceding claims and a carrier.

8. The composition of claim 7, wherein the composition is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier.

9. An antibody or antigen-binding portion thereof for use in medicament, wherein the antibody or antigen-binding portion thereof is any of claims 1-6.

10. Use of the antibody or antigen-binding portion thereof of any of claims 1-6 in the manufacture of a medicament for treating a disease or condition associated with Yellow Fever Virus.

11. A nucleic acid comprising a nucleotide sequence encoding an antibody heavy chain variable region (VH), an antibody light chain variable region (VL) or both, wherein the VH and VL is set forth in claim 2 or 3.

12. A vector comprising the nucleic acid of claim 11.

13. The vector of claim 12, wherein the vector is an expression vector.

14. A host cell comprising the nucleic acid of claim 11 or the vector of claim 12 or 13.

15. A method for producing an antibody or antigen-binding portion thereof, comprising:

culturing the host cell of claim 14 under conditions allowing for expression of the antibody.

16. The method of claim 15, further comprising harvesting the antibody or antigen-binding portion thereof.